Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 320

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 320
---
 of a particular medical condition, the preference for our product candidate over competing therapies, and the size of patient
populations. Some or all of these assumptions might prove to be inaccurate because our ability to predict whether our product candidates
will attain significant market acceptance or if a market for our product candidates will indeed materialize as anticipated, is inherently
uncertain. If any of these assumptions turn out to be incorrect or overly optimistic, it could have a substantial and adverse impact on
our results and future prospects.

Our future success depends on our ability to retain key employees,
directors, consultants and advisors and to attract, retain and motivate qualified personnel.

We heavily depend on the expertise of our executive officers, directors,
and scientific teams for their expertise in areas such as management, research and development, drug development, finance, and business
development, both for the Company and our subsidiaries and investments. Their departure could adversely impact our research, development,
and our licensing pursuits, and impede the execution of our business strategy. We do not carry “key person” insurance for
our executives or staff so that replacing them might be challenging due to our inability to pay premium salaries or signing bonuses, together
with the scarcity of individuals with the required breadth of skills and experience in our industry. We might struggle to attract, train,
retain, or motivate them given the numerous competing pharmaceutical and biotechnology companies.

Our reliance on a central team consisting of a limited number
of employees who provide various administrative, research and development and other services to all our subsidiaries presents operational
challenges that may adversely affect our business.

As of December 31, 2024, we had 19 full-time employees and
two part-time employees whom we rely on for drug development planning, employee relations, financing accounting matters and other
support services for our company and all of its subsidiaries. These individuals may not have sufficient time and bandwidth to perform
effectively their respective responsibilities, potentially hindering the achievement of our goals and jeopardizing the execution of our
business strategy. While our current structure helps us minimize certain overhead expenses, the relatively small size of our central team
limits our ability to allocate enough personnel, time, and resources to effectively manage our subsidiaries and investments creation of
effective drug development plans, employee recruitment and retention, and overseeing financial and accounting matters. Members of our
central team may lack sufficient information about various aspects of our subsidiaries’ business and operations to adequately address
these responsibilities.

43

We will need to expand our organization, and we may experience